In a subanalysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness trial (ESCAPE), Nohria et al. demonstrated a significant correlation between baseline renal function and the CVP, there was, however no correlation between baseline renal function and cardiac index, pulmonary capillary wedge pressure or systemic vascular resistance [85].
For instance, Yavuz et al. reported that a 78-year-old female with normal baseline renal function, and no contributing possible nephrotoxic factors, developed irreversible renal dysfunction after oral ACV treatment [9].
However, while being designed primarily for longitudinal assessment of baseline renal function and validated merely in chronic kidney failure, creatinine-based decision-making in critically ill patients is debatable [4, 5].
Demographic data (age, sex, actual body weight, body mass index (BMI), baseline renal function, and comorbid conditions), severity of illness score (APACHEII) calculated at the time of ICU admission, Sequential Organ Failure Assessment score (SOFA score) at the commencement of vancomycin, and laboratory parameters were retrospectively collected for each patient in the study.
*Adjusted for age, sex, diabetes, baseline renal function, and number of prescribed drugs.
Renal function monitoring is recommended every 3 12 months, depending on the patient's baseline renal function and antiretroviral regimen.
Our study's strengths include use of a robust database that comprises clinically relevant measures of comorbidity, baseline renal function, biochemical and hemodynamic indices, and acute illness severity.
Compared with IgAN/ANCA– patients, IgAN/ANCA+ were older and had worse baseline renal function, more lung and systemic involvement and more fibrinoid necrosis in renal histology.
Two patients had full renal recovery to their baseline renal function at 7 and 14 days.
The effects of baseline renal function, comorbidities, age, and duration of renal injury have led to conflicting results in various studies (Table 3).
The prognostic use of sUA differs by baseline renal function, suggesting different biologic and pathophysiologic significance of sUA among those with and without significant renal dysfunction.
